JP2019532084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532084A5 JP2019532084A5 JP2019520928A JP2019520928A JP2019532084A5 JP 2019532084 A5 JP2019532084 A5 JP 2019532084A5 JP 2019520928 A JP2019520928 A JP 2019520928A JP 2019520928 A JP2019520928 A JP 2019520928A JP 2019532084 A5 JP2019532084 A5 JP 2019532084A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound according
- heteroaryl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006735 (C1-C20) heteroalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 claims 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229940029575 guanosine Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 229960000487 sorafenib tosylate Drugs 0.000 claims 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000009377 thymus cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078657A JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359039P | 2016-07-06 | 2016-07-06 | |
| US62/359,039 | 2016-07-06 | ||
| US201662363118P | 2016-07-15 | 2016-07-15 | |
| US62/363,118 | 2016-07-15 | ||
| US201662403530P | 2016-10-03 | 2016-10-03 | |
| US62/403,530 | 2016-10-03 | ||
| US201662411424P | 2016-10-21 | 2016-10-21 | |
| US62/411,424 | 2016-10-21 | ||
| US201762444141P | 2017-01-09 | 2017-01-09 | |
| US62/444,141 | 2017-01-09 | ||
| US201762462679P | 2017-02-23 | 2017-02-23 | |
| US62/462,679 | 2017-02-23 | ||
| US201762470746P | 2017-03-13 | 2017-03-13 | |
| US62/470,746 | 2017-03-13 | ||
| US201762508846P | 2017-05-19 | 2017-05-19 | |
| US62/508,846 | 2017-05-19 | ||
| PCT/US2017/040882 WO2018009648A1 (en) | 2016-07-06 | 2017-07-06 | Compounds, compositions, and methods for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078657A Division JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532084A JP2019532084A (ja) | 2019-11-07 |
| JP2019532084A5 true JP2019532084A5 (enExample) | 2020-08-06 |
| JP7100227B2 JP7100227B2 (ja) | 2022-07-13 |
Family
ID=60913147
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520928A Active JP7100227B2 (ja) | 2016-07-06 | 2017-07-06 | 疾患の治療のための化合物、組成物、および方法 |
| JP2022078657A Pending JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A Active JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078657A Pending JP2022106989A (ja) | 2016-07-06 | 2022-05-12 | 疾患の治療のための化合物、組成物、および方法 |
| JP2023162456A Active JP7749629B2 (ja) | 2016-07-06 | 2023-09-26 | 疾患の治療のための化合物、組成物、および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11033569B2 (enExample) |
| EP (1) | EP3481402A4 (enExample) |
| JP (3) | JP7100227B2 (enExample) |
| KR (1) | KR102569881B1 (enExample) |
| CN (1) | CN109843302B (enExample) |
| AU (1) | AU2017293781B2 (enExample) |
| CA (1) | CA3029644A1 (enExample) |
| IL (1) | IL264049B2 (enExample) |
| MX (2) | MX392605B (enExample) |
| MY (1) | MY199689A (enExample) |
| NZ (1) | NZ750055A (enExample) |
| SG (1) | SG11201811709WA (enExample) |
| TW (1) | TWI689514B (enExample) |
| WO (1) | WO2018009648A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| AU2017293781B2 (en) * | 2016-07-06 | 2022-12-22 | Invox Pharma Limited | Compounds, compositions, and methods for the treatment of disease |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| IL315837A (en) | 2017-04-13 | 2024-11-01 | Sairopa B V | Anti-SIRP-alpha antibodies |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| WO2020014127A1 (en) * | 2018-07-10 | 2020-01-16 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| LT3848054T (lt) | 2018-09-06 | 2025-03-25 | Daiichi Sankyo Company, Limited | Ciklinių dinukleotidų darinių antikūno ir vaisto konjugatai |
| MX2021003207A (es) | 2018-09-21 | 2021-06-23 | Shanghai De Novo Pharmatech Co Ltd | Analogo de dinucleotido ciclico. composicion farmaceutica del mismo y su aplicacion. |
| US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| EP3873938A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody conjugates comprising sting agonists |
| EP3901161B1 (en) * | 2019-01-10 | 2025-01-22 | Shenzhen YING Biopharmaceutical Co., Ltd. | Cyclic dinucleotide prodrug molecule, preparation method therefor and application thereof |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| JP7621974B2 (ja) | 2019-05-09 | 2025-01-27 | アリゴス セラピューティクス インコーポレイテッド | Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物 |
| EP3993834A1 (en) | 2019-07-05 | 2022-05-11 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| IL296124A (en) | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| JPWO2021206158A1 (enExample) | 2020-04-10 | 2021-10-14 | ||
| CN111909223A (zh) * | 2020-07-17 | 2020-11-10 | 清华大学 | 环二核苷酸共价修饰物及其制备方法和应用 |
| US20230256109A1 (en) | 2020-08-07 | 2023-08-17 | Tambo, Inc. | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy |
| CN116113641A (zh) | 2020-09-02 | 2023-05-12 | 第一三共株式会社 | 新型内－β－N－乙酰氨基葡萄糖苷酶 |
| TW202233251A (zh) | 2020-11-09 | 2022-09-01 | 日商武田藥品工業股份有限公司 | 抗體藥物綴合物 |
| WO2023167238A1 (ja) | 2022-03-02 | 2023-09-07 | 第一三共株式会社 | Ｆｃ含有分子の製造方法 |
| EP4582106A1 (en) | 2022-08-29 | 2025-07-09 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| WO2024076728A1 (en) * | 2022-10-06 | 2024-04-11 | Dana-Farber Cancer Institute, Inc. | Cyclic nucleotides and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) * | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| ES2569927T3 (es) * | 2003-06-11 | 2016-05-13 | Idera Pharmaceuticals, Inc. | Oligonucleótidos inmunomoduladores estabilizados |
| US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| AU2005222626B2 (en) * | 2004-03-15 | 2010-05-20 | Karagen Pharmaceuticals, Inc. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| WO2011003025A1 (en) * | 2009-07-01 | 2011-01-06 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| CN102199183B (zh) * | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| CN104507538B (zh) | 2012-06-08 | 2018-04-06 | 艾杜罗生物科技公司 | 癌症免疫疗法的组合物和方法 |
| SG11201502796RA (en) * | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| WO2014099824A1 (en) * | 2012-12-19 | 2014-06-26 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| EP2935616B1 (en) * | 2012-12-20 | 2018-02-28 | Hill's Pet Nutrition, Inc. | Pattern recognition receptor expression as a measure of systemic health |
| JP6153116B2 (ja) * | 2013-01-09 | 2017-06-28 | 国立大学法人東北大学 | トリアゾール連結型環状ジヌクレオチド類縁体 |
| CN103961306A (zh) * | 2013-02-05 | 2014-08-06 | 日东电工株式会社 | 经皮给予用疫苗组合物 |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉ型インターフェロンの環状ジヌクレオチド誘導法 |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| CN103864910B (zh) * | 2014-03-03 | 2016-01-20 | 中国科学院南海海洋研究所 | 一种新型特异结合lps的贝类模式识别受体lrrp |
| US10144778B2 (en) | 2014-03-12 | 2018-12-04 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR20170015353A (ko) | 2014-06-04 | 2017-02-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Ｓｔｉｎｇ의 조절제로서 사이클릭 디뉴클레오타이드 |
| US20170340658A1 (en) | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| CN107148424B (zh) * | 2014-12-16 | 2021-01-08 | 凯拉治疗股份公司 | 用于诱导细胞因子的环状二核苷酸 |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| JP6692826B2 (ja) * | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
| BR112018002757A8 (pt) | 2015-08-13 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio |
| AU2016343993A1 (en) | 2015-10-28 | 2018-05-10 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| JP6411676B2 (ja) * | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| CN106540260A (zh) | 2015-12-09 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 干扰素基因刺激蛋白（sting）激动剂在抗阿尔兹海默症中的应用 |
| US20180369268A1 (en) * | 2015-12-16 | 2018-12-27 | Aduro Biotech, Inc. | Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production |
| KR20250049441A (ko) | 2016-01-11 | 2025-04-11 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| KR20180114946A (ko) | 2016-03-02 | 2018-10-19 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 면역요법을 위한 sting 활성화 나노백신 |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| AU2017293781B2 (en) * | 2016-07-06 | 2022-12-22 | Invox Pharma Limited | Compounds, compositions, and methods for the treatment of disease |
| WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| EP3523287B1 (en) | 2016-10-04 | 2021-09-01 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene compounds as sting agonists |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| AU2017378782A1 (en) | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| US20200113924A1 (en) | 2016-12-20 | 2020-04-16 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| EP3585379A4 (en) | 2017-02-21 | 2020-12-02 | Board of Regents, The University of Texas System | CYCLIC DINUCLEOTIDES USED AS AGONISTS OF THE INTERFERON-DEPENDENT SIGNALING STIMULATOR |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| EP3621624B1 (en) | 2017-05-12 | 2023-08-30 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| EP3642198B1 (en) | 2017-06-22 | 2022-03-16 | Curadev Pharma Limited | Small molecule modulators of human sting |
| EP3642184A1 (en) | 2017-06-22 | 2020-04-29 | Curadev Pharma Limited | Small molecule modulators of human sting |
| WO2019051489A1 (en) * | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
-
2017
- 2017-07-06 AU AU2017293781A patent/AU2017293781B2/en active Active
- 2017-07-06 NZ NZ750055A patent/NZ750055A/en unknown
- 2017-07-06 TW TW106122757A patent/TWI689514B/zh active
- 2017-07-06 WO PCT/US2017/040882 patent/WO2018009648A1/en not_active Ceased
- 2017-07-06 SG SG11201811709WA patent/SG11201811709WA/en unknown
- 2017-07-06 MX MX2019000216A patent/MX392605B/es unknown
- 2017-07-06 IL IL264049A patent/IL264049B2/en unknown
- 2017-07-06 CA CA3029644A patent/CA3029644A1/en active Pending
- 2017-07-06 KR KR1020197003440A patent/KR102569881B1/ko active Active
- 2017-07-06 US US16/315,472 patent/US11033569B2/en active Active
- 2017-07-06 MY MYPI2019000212A patent/MY199689A/en unknown
- 2017-07-06 CN CN201780054031.7A patent/CN109843302B/zh active Active
- 2017-07-06 EP EP17824876.1A patent/EP3481402A4/en active Pending
- 2017-07-06 JP JP2019520928A patent/JP7100227B2/ja active Active
-
2019
- 2019-01-07 MX MX2022006260A patent/MX2022006260A/es unknown
-
2021
- 2021-06-04 US US17/339,484 patent/US11744845B2/en active Active
-
2022
- 2022-05-12 JP JP2022078657A patent/JP2022106989A/ja active Pending
-
2023
- 2023-09-26 JP JP2023162456A patent/JP7749629B2/ja active Active